St Etienne Cedex 2

• Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imag … Recruiting
  2023-507482-26-00 5 2024-10-04 Castrate-resistant prostate cancer with oligometastases on functional
• Tocolysis in cases of preterm premature rupture of membranes (PPROM) before 34 weeks of gestation: a double-blinded randomized controlled tr … Recruiting
  2024-512872-36-00 5 2024-07-25 obstetric_pathological delivery
• StAtins for Venous Event Reduction in Patients with Venous Thromboembolism : The SAVER Trial Recruiting
  2023-504486-23-00 5 2024-05-29 Venous thromboembolism
• Benefit of transplantation after Complete Response In Patients with T-cell lymphoma Recruiting
  2022-501710-62-02 6 2023-06-07 Peripheral T-cell lymphoma (PTCL)
• Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients Recruiting
  2023-508594-84-00 4 2022-01-11 Metastatic pancreatic adenocarcinoma
• STUDY TO ASSESS THE SCHEMAS OF RETREATMENT WITH LUTATHERA® IN PATIENTS WITH NEW PROGRESSION OF INTESTINAL WELL-DIFFERENTIATED NEUROENDOCRINE … Recruiting
  2024-511001-28-00 4 2021-12-13 Neuroendocrine tumor
• RETINO 2018: conservative treatment for retinoblastoma: efficacy of the new management strategies and visual outcome Recruiting
  2024-514025-30-00 4 2021-03-25 Ocular conservative treatment for retinoblastoma
• CHASAP : Chronic Hypertension and Acetyl Salicylic Acid in Pregnancy, a multicenter prospective randomized double-blind placebo-controlled t … Recruiting
  2024-516461-36-00 5 2021-01-27 Pregnancy associated hypertension, Pre-Eclampsia, Fetal growth restric
• International study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the effica … Recruiting
  2022-501454-11-00 5 2020-02-05 standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
• SIOP RANDOMET 2017 Recruiting
  2023-508926-91-00 5 2019-12-05 Stage IV childhood renal tumour with pulmonary +/- non-pulmonary metas
• CLAZI : CLArithromycin versus AZIthromycin in the treatment of Mycobacterium avium complex pulmonary infections: A randomized prospective co … Recruiting
  2024-518578-15-00 5 2018-02-05 Is to demonstrate a non inferior efficacy of azithromycin and so the p
• Hyperthermic Intraperitoneal Chemotherapy in the treatment of Ovarian Cancer relapse Recruiting
  2024-517390-24-00 5 2011-04-26 Ovarian epithelial cancer : intraperitoneal resectable relapse
• A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active … Ended recruitment
  2024-516213-20-00 5 2025-03-25 Psoriatic arthritis
• A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL C … Ended recruitment
  2024-514032-25-00 4 2024-12-11 Patients with a histilogically confirmed diagnosis of cervical squamou
• A Study to Compare the Efficacy and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants with Previously Untreated High- … Ended recruitment
  2023-510178-15-00 5 2024-07-31 High-risk Large B-cell Lymphoma
• TocilizuMab discontinuAtion in GIant Cell Arteritis Ended recruitment
  2023-505515-21-00 5 2024-04-02 Giant Cell Arteritis
• PRODIGE 85 (FFCD 1804) – KANALRAD Prospective randomized phase III study evaluating induction chemotherapy (modified DCF 4 cycles) followed … Ended recruitment
  2023-505972-32-00 5 2024-02-26 locally advanced anal squamous cell carcinoma
• A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB … Ended recruitment
  2023-506139-13-00 5 2024-01-04 Treatment naïve patients with MF
• Treatment pause versus treatment continuation in good or intermediate risk with only one adverse prognostic factor in mRCC patients that has … Ended recruitment
  2024-514644-93-00 5 2022-12-09 Metastatic renal cell carcinoma (mRCC) with a good or only one adverse
• Clinical Study of Fianlimab in Combination With Cemiplimab versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated U … Ended recruitment
  2023-505772-30-00 5 2022-11-09 Melanoma
• Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus Dostarlimab in first line advanc … Ended recruitment
  2023-510097-14-00 5 2022-04-15 Patients with MMR deficient relapse or advanced / metastatic endometri
• Assessment of Flecainide to Lower the patent foramen Ovale closure risk of Atrial arrhythmia or Tachycardia Ended recruitment
  2024-513324-42-00 5 2022-03-23 Patent Foramen Ovale Closure Atrial Arrhytmia or Tachycardia
• Evaluation of two maintenance therapies (OSE2101 alone or in combination with pembrolizumab) versus best supportive care in patient with pla … Ended recruitment
  2024-516096-32-00 4 2021-08-05 Platinum sensitive recurrent ovarian cancer
• Clinical trial comparing Trastuzumab Deruxtecan with Trastuzumab Emtansine in high-risk HER2-positive patients with residual breast cancer f … Ended recruitment
  2023-507961-24-00 5 2021-04-19 High-Risk HER2-Positive Breast Cancer

Showing 25–48 of 61 trials